OraSure Technologies 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 15, 2012
OraSure Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
Registrants telephone number, including area code: 610-882-1820
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Item 5.07 Submission of Matters to a Vote of Security Holders.
The following is a summary of the items considered by stockholders and the corresponding voting results at the OraSure Technologies, Inc. (the Company) Annual Meeting of Stockholders held on May 15, 2012:
Item 1 Election of Class III Directors for Terms Expiring at the 2015 Annual Meeting of Stockholders.
Item 2 Ratification of Appointment of KPMG, LLP as the Companys Independent Registered Public Accounting Firm for 2012.
Item 3 Non-Binding Advisory Resolution Approving Executive Compensation.
Item 7.01 Regulation FD Disclosure.
On May 15, 2012, the Company issued a press release announcing the results of the U.S. Food and Drug Administrations Blood Products Advisory Committee review of the Companys application for premarket approval of its OraQuick® In-Home HIV test for sale in the U.S. consumer or over-the-counter market. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Index to Exhibits